Journal
SEMINARS IN THROMBOSIS AND HEMOSTASIS
Volume 38, Issue 4, Pages 322-327Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0032-1304719
Keywords
antiphospholipid antibodies; lupus anticoagulant; beta(2)-glycoprotein I
Categories
Ask authors/readers for more resources
Venous or arterial thrombosis or pregnancy morbidity in the presence of circulating antiphospholipid antibodies (aPL) define the antiphospholipid syndrome (APS). In terms of accepted APS criteria, aPL are detected by one coagulation test (lupus anticoagulant; LAC) and two immunoassays (anticardiolipin antibodies and anti-beta(2)-glycoptrotein I antibodies). In patients with APS, a single positive test carries a much lower risk of thrombosis recurrence or new pregnancy loss than does multiple (or triple) positivity. The same holds true for aPL carriers, namely subjects with laboratory tests but without clinical criteria for APS. Thus, very different risk categories exist among patients with APS as well as in carriers of aPL. Triple positivity apparently identifies the pathogenic autoantibody (antidomain I-II of beta(2)-glycoptrotein I); it is in this category of patients that trials on new therapeutic strategies should focus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available